Bayer (FRA:BAYN) PT Set at €70.00 by Credit Suisse Group
Credit Suisse Group set a €70.00 ($81.40) target price on Bayer (FRA:BAYN) in a report issued on Thursday, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
BAYN has been the topic of a number of other research reports. Barclays set a €85.00 ($98.84) target price on shares of Bayer and gave the company a buy rating in a research report on Tuesday, May 14th. HSBC set a €63.00 ($73.26) price target on shares of Bayer and gave the stock a neutral rating in a report on Monday, July 1st. Sanford C. Bernstein set a €89.00 ($103.49) price target on shares of Bayer and gave the stock a buy rating in a report on Tuesday, May 14th. Societe Generale set a €65.00 ($75.58) price target on shares of Bayer and gave the stock a neutral rating in a report on Wednesday, March 27th. Finally, DZ Bank reiterated a buy rating on shares of Bayer in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of Hold and an average target price of €80.63 ($93.76).
Shares of BAYN opened at €60.71 ($70.59) on Thursday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98). The company has a 50-day simple moving average of €55.48.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: What is the Coverage Ratio?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.